Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
(1) Metformin Hydrochloride Extended-release Tablets USP should not be used in patients with renal disease, acute or chronic metabolic acidosis, impaired liver dysfunction or who have a known hypersensitivity. Patients who have congestive heart failure, renal disease or are elderly are at increased risk of Lactic acidosis. In patients suffering from hypoxemia, dehydration or sepsis, Metformin Hydrochloride should be withheld.
SOURCE Mylan Inc.